Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis

BACKGROUND: Alcoholic fatty liver disease (AFLD) is characterized by hepatic steatosis and carries an elevated risk of cirrhosis and hepatocellular carcinoma. However, the mechanism of AFLD has not been elucidated thoroughly, and there are still no efficient therapies in clinic. Notably, butyrate, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ting, Li, Jun, Liu, Cui-Ping, Guo, Man, Gao, Chen-Lin, Zhou, Lu-Ping, Long, Yang, Xu, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184481/
https://www.ncbi.nlm.nih.gov/pubmed/34164507
http://dx.doi.org/10.21037/atm-21-2158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184481/
https://www.ncbi.nlm.nih.gov/pubmed/34164507
http://dx.doi.org/10.21037/atm-21-2158

Ejemplares similares